Characterizing attributes of innovation of technologies for healthcare: a systematic review

References

• Aronson JK. Something new every day: defining innovation and innovativeness in drug therapy. J Ambul Care Manage. 2008;31(1):65–68.
   PubMedGoogle Scholar
• WHO Health Innovation Group. How does WHIG define health. Scotpublichealth. 2020. Available from: https://scotpublichealth.com/2020/04/26/health-innovationand-covid-19-pandemic-defining-the-need-and-understanding-theresponse/
   Google Scholar
• Herzlinger RE. Why innovation in health care is so hard. Harv Bus Rev. 2006;84(5):58–66, 156.
   PubMed Web of Science ®Google Scholar
• Charlton V, Rid A. Innovation as a value in healthcare priority-setting: the UK experience. Soc Justice Res. 2019;32(2):208–238.
   Web of Science ®Google Scholar
• Fortinguerra F, Tafuri G, Trotta F, et al. Using GRADE methodology to assess innovation of new medicinal products in Italy. Br J Clin Pharmacol. 2020;86(1):93–105.
   PubMed Web of Science ®Google Scholar
• Assessment ENfHT. What is Health Technology Assessment (HTA). Available from: https://www.eunethta.eu/services/submission-guidelines/pharmaceutical-submission/#ptfaq1
   Google Scholar
• Torbica A, Tarricone R, Drummond M. Does the approach to economic evaluation in health care depend on culture, values, and institutional context? Eur J Health Econ. 2018;19:769–774.
   PubMed Web of Science ®Google Scholar
• Westrich K. Current landscape: value assessment frameworks. Washington (DC): National Pharmaceutical Council; 2016.
   Google Scholar
• Ciani O, Armeni P, Boscolo PR, et al. De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making. Health Policy Technol. 2016;5(1):47–64.
   Web of Science ®Google Scholar
• de Solà-Morales O, Cunningham D, Flume M, et al. Defining innovation with respect to new medicines: a systematic review from a payer perspective. Int J Technol Assess Health Care. 2018;34(3):224–240.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Joseph ML, Huber DL, Bair H, et al. A typology of innovations in nursing. J Nurs Adm. 2019;49(7–8):389–395.
   PubMed Web of Science ®Google Scholar
• Karampli E, Souliotis K, Polyzos N, et al. Why do physicians prescribe new antidiabetic drugs? A qualitative study in the Greek healthcare setting. Health Policy Technol. 2020;9(2):166–173.
   Web of Science ®Google Scholar
• NICE Citizens Council. NICE citizens council reports. Health innovation and value. London: National Institute for Health and Care Excellence (NICE) Copyright © 2009 National Institute for Health and Clinical Excellence; 2009.
   Google Scholar
• Billaux M, Borget I, Prognon P, et al. Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians. Aust Health Rev. 2016;40(3):257–261.
   PubMed Web of Science ®Google Scholar
• Sheard L, Jackson C, Lawton R. How is success achieved by individuals innovating for patient safety and quality in the NHS? BMC Health Serv Res. 2017;17(1):1–9.
   PubMedGoogle Scholar
• Nicod E, Brigham KB, Durand-Zaleski I, et al. Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs: evidence from four European countries. Value Health. 2017;20(7):919–926.
   PubMed Web of Science ®Google Scholar
• McGloughlin EK, Anglim P, Keogh I, et al. Innovation for the future of Irish MedTech industry: retrospective qualitative review of impact of BioInnovate Ireland’s clinical fellows. BMJ Innov. 2018;4(1):32–38.
   PubMedGoogle Scholar
• Florindi F, De Lorenzo F, Apostolidis K, et al. Value of innovation in oncology: the position of European cancer patients on access to innovative treatments. Am Soc Clin Oncol. 2017;35(15_suppl):e18021–e18021.
   Google Scholar
• Jonker CJ, van den Berg HM, Kwa MS, et al. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf. 2017;26(12):1451–1457.
   PubMed Web of Science ®Google Scholar
• Lakdawalla D, Malani A, Reif J. The insurance value of medical innovation. J Public Econ. 2017;145:94–102.
   Web of Science ®Google Scholar
• Hamilton BH, Hincapié A, Miller RA, et al. Innovation and diffusion of medical treatment. Cambridge (MA): National Bureau of Economic Research; 2018.
   Google Scholar
• Mestre-Ferrandiz JM, Sussex J. The many faces of innovation. A report for the ABPI by the Office of Health Economics. London (UK): Association of the British Pharmaceutical Industry; 2012. Available from: https://www.ohe.org/system/files/private/publications/373%20-%20Many_Faces_of_Innovation_Mestre-Ferrandiz_2012.pdf?download=1
   Google Scholar
• Dhar M, Griffin M, Hollin I, et al. Innovation spaces: six strategies to inform health care. Health Care Manag (Frederick). 2012;31(2):166–177.
   PubMedGoogle Scholar
• Ferlie E, Nicolini D, Ledger J, et al. NHS top managers, knowledge exchange and leadership: the early development of academic health science networks–a mixed-methods study. Health Serv Deliv Res. 2017;5(17):1–204.
   Google Scholar
• Monia M. Value of innovation for hematologic malignancies. J Med Econ. 2016;19(5):487–489.
   PubMed Web of Science ®Google Scholar
• Lanzafame RJ. Responsibilities and innovation. New Rochelle (NY): Mary Ann Liebert, Inc.; 2010.
   Google Scholar
• Miller KL, Lanthier M. Trends in orphan new molecular entities, 1983–2014: half were first in class, and rare cancers were the most frequent target. Health Aff (Millwood). 2016;35(3):464–470.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. F1000Res. 2020;9:944.
   Google Scholar
• Baum RA, Baum S. Interventional radiology: a half century of innovation. Radiology. 2014;273(2 Suppl):S75–S91.
   PubMedGoogle Scholar
• Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? Drug Discov Today. 2011;16(23–24):1037–1043.
   PubMed Web of Science ®Google Scholar
• Petykó ZI, Inotai A, Holtorf A-P, et al. Barriers and facilitators of exploiting the potential of value-added medicines. Expert Rev Pharmacoecon Outcomes Res. 2020;20(3):229–236.
   PubMed Web of Science ®Google Scholar
• Roubou I, Alexopoulou DK. The various shapes of innovation. Forum Clin Oncol. 2015;6(4):12–22.
   Google Scholar
• Bryan S, Lee H, Mitton C. ‘Innovation’ in health care coverage decisions: all talk and no substance? J Health Serv Res Policy. 2013;18(1):57–60.
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P. Multiple criteria decision analysis (MCDA) for evaluating new medicines in health technology assessment and beyond: the advance value framework. Soc Sci Med. 2017;188:137–156.
   PubMed Web of Science ®Google Scholar
• Consoli D, Mina A. An evolutionary perspective on health innovation systems. J Evol Econ. 2009;19(2):297–319.
   Web of Science ®Google Scholar
• Ellner AL, Stout S, Sullivan EE, et al. Health systems innovation at academic health centers: Leading in a new era of health care delivery. Acad Med. 2015;90(7):872–880.
   PubMed Web of Science ®Google Scholar
• Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6(9):550–552.
   PubMed Web of Science ®Google Scholar
• Hübner U. What are complex eHealth innovations and how do you measure them? Methods Inf Med. 2015;54(4):319–327.
   PubMed Web of Science ®Google Scholar
• Quinn C, Palmer S, Bruns J, editors. Innovation in oncology: why focusing only on breakthrough innovation may be counter-productive. Haematologica. Pavia (Italy): Ferrata Storti Foundation; 2015.
   Google Scholar
• Pammolli F, Riccaboni M. Market structure and drug innovation. Health Aff (Millwood). 2004;23(1):48–50.
   PubMed Web of Science ®Google Scholar
• Ferner R, Hughes DA, Aronson J. NICE and new: appraising innovation. BMJ. 2010;340(jan05 2):b5493–b5493.
   PubMedGoogle Scholar
• Quinn C, Palmer S, Bruns J, et al. Progressive innovation in oncology: valuing outcomes beyond survival. Value in Health. 2015;18(7):A482.
   Web of Science ®Google Scholar
• Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer. 1999;35(14):2010–2030.
   PubMed Web of Science ®Google Scholar
• Conti RM. Economic value of new treatments for depression. PhD dissertation. Harvard University; 2006. Available from: https://scholar.google.com/scholar?cluster=6395544026005408420&hl=en&as_sdt=5,45
   Google Scholar
• Costa LS. Innovation in healthcare services: notes on the limits of field research. Cad Saude Publica. 2016;32:e00151915.
   Web of Science ®Google Scholar
• Chagpar AB. Innovation in surgery: from imagination to implementation. Am J Surg. 2011;202(6):641–645.
   PubMed Web of Science ®Google Scholar
• Biddiscombe MF, Usmani OS. Is there room for further innovation in inhaled therapy for airways disease? Breathe (Sheff). 2018;14(3):216–224.
   PubMedGoogle Scholar
• Chan TY, Hamilton BH, Papageorge NW. Health, risky behaviour and the value of medical innovation for infectious disease. Rev Econ Stud. 2016;83(4):1465–1510.
   Web of Science ®Google Scholar
• Bhatti Y, Taylor A, Harris M, et al. Global lessons in frugal innovation to improve health care delivery in the United States. Health Aff (Millwood). 2017;36(11):1912–1919.
   PubMed Web of Science ®Google Scholar
• Papageorge NW. Why medical innovation is valuable: Health, human capital, and the labor market. Quant Econ. 2016;7(3):671–725.
   Google Scholar
• Zaim R, Tran L, Groen H, et al. ‘DE NOVO’Quantification of genotype-directed therapy with afatinib in metastatic lung cancer. Value Health. 2014;17(7):A641.
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Messina JC, Mahmoud RA. Breath powered nasal delivery: a new route to rapid headache relief. Headache. 2013;53(S2):72–84.
   PubMedGoogle Scholar
• Rezvani M, Hesari J, Peighambardoust SH, et al. Development and characterization of nanostructured pharmacosomal mesophases: an innovative delivery system for bioactive peptides. Adv Pharm Bull. 2018;8(4):609–615.
   PubMed Web of Science ®Google Scholar
• Graziottin A. Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review. Patient Prefer Adherence. 2008;2:357–367.
   PubMedGoogle Scholar
• Stephanie W, Hill C, Ricks ML, et al. The scope and impact of mobile health clinics in the United States: a literature review. Int J Equity Health. 2017;16(1):1–12.
   PubMedGoogle Scholar
• Balducci AG, Magosso E, Colombo G, et al. From tablets to pharmaceutical nanotechnologies: Innovation in drug delivery strategies for the administration of antimalarial drugs. J Drug Delivery Sci Technol. 2016;32:167–173.
   Web of Science ®Google Scholar
• Moreira M, Sarraguça M. How can oral paediatric formulations be improved? A challenge for the XXI century. Int J Pharm. 2020;590:119905.
   PubMedGoogle Scholar
• Belloso WH. On innovation. Ther Innov Regul Sci. 2020;54(5):1068–1075.
   PubMed Web of Science ®Google Scholar
• Henshall C, Schuller T. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29(4):353–359.
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Young AJ. Promoting innovation in healthcare. Future Healthc J. 2017;4(2):121–125.
   PubMedGoogle Scholar
• Toskin I, Blondeel K, Peeling RW, et al. Advancing point of care diagnostics for the control and prevention of STIs: the way forward. Sex Transm Infect. 2017;93(S4):S81–S88.
   PubMedGoogle Scholar
• Hartmann J, Schüßler‐Lenz M, Bondanza A, et al. Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–1197.
   PubMed Web of Science ®Google Scholar
• Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011;29(11):550–557.
   PubMed Web of Science ®Google Scholar
• Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124.
   PubMed Web of Science ®Google Scholar
• Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020;37(5):2034–2049.
   PubMed Web of Science ®Google Scholar
• Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol. 2001;13:S43–S47.
   PubMed Web of Science ®Google Scholar
• Ye Z, Chen J, Xuan Z, et al. Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:1707–1716.
   PubMed Web of Science ®Google Scholar
• Bell E, Neri M, Steuten L. Towards a broader assessment of value in vaccines: the BRAVE way forward. Appl Health Econ Health Policy. 2022;20(1):105–117.
   PubMed Web of Science ®Google Scholar
• Harris M, Bhatti Y, Prime M, et al. Low-cost innovation in healthcare: what you find depends on where you look. J R Soc Med. 2018;111(2):47–50.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, Jr, et al. Defining elements of value in health care- a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Hofmann S, Branner J, Misra A, et al. A review of current approaches to defining and valuing innovation in health technology assessment. Value Health. 2021;24(12):1773–1783.
   PubMed Web of Science ®Google Scholar
• Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123–152.
   PubMed Web of Science ®Google Scholar
• Tutone M, Villa F, Addis A, et al. How do drug regulatory bodies deal with potential innovative therapies? Ther Innov Regul Sci. 2020;54(1):195–199.
   PubMed Web of Science ®Google Scholar
• Rejon-Parrilla JC, Espin J, Epstein D. How innovation can be defined, evaluated and rewarded in health technology assessment. Health Econ Rev. 2022;12(1):1–11.
   PubMed Web of Science ®Google Scholar
• Basch E, Aronson N, Berg A, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA. 2012;307(15):1636–1640.
   PubMed Web of Science ®Google Scholar
• Frank L, Basch E, Selby JV, et al. The PCORI perspective on patient-centered outcomes research. Jama. 2014;312(15):1513–1514.
   PubMed Web of Science ®Google Scholar